Charles River Laboratories International (CRL) Stock Price, News & Analysis

Company Overview

Charles River Laboratories International, Inc. is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing. Charles River also provides microbial solutions, biologics and chemistry services, and support for cell and gene therapy development and manufacturing. These services are designed to help customers evaluate potential therapies and advance them toward clinical development.

Founded in 1947, Charles River Laboratories serves customers through operations in North America, Europe, Asia and other international markets. The company is headquartered in Wilmington, Massachusetts, and has built its business through a combination of internal capabilities and acquisitions across the life sciences services industry.

Key Stats

• Today's Range: $274.40 to $285.58
• 50-Day Range: $218.44 to $298.76
• 52-Week Range: $144.26 to $303.30
• Volume: 809,827 shs
• Average Volume: 831,340 shs
• Market Capitalization: $13.44 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $273.81
• Consensus Rating: Moderate Buy

Charles River Laboratories International Stock Analysis - MarketRank™

Charles River Laboratories International scored higher than 44% of companies evaluated by MarketBeat, and ranked 630th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Charles River Laboratories International has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 11 buy ratings, 3 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Charles River Laboratories International is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Charles River Laboratories International has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 11.12%

Earnings Growth

Earnings for Charles River Laboratories International are expected to grow by 11.12% in the coming year, from $11.33 to $12.59 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Charles River Laboratories International is -58.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Charles River Laboratories International is -58.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Charles River Laboratories International has a PEG Ratio of 2.68. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Charles River Laboratories International has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.38% of the float of Charles River Laboratories International has been sold short.

Short Interest Ratio / Days to Cover

Charles River Laboratories International has a short interest ratio ("days to cover") of 2.78, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Charles River Laboratories International has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Charles River Laboratories International does not currently pay a dividend.

Dividend Growth

Charles River Laboratories International does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.07

News Sentiment

Charles River Laboratories International has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Charles River Laboratories International this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for CRL on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

3 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Charles River Laboratories International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,606,388.00 in company stock.

Percentage Held by Insiders

1.30% of the stock of Charles River Laboratories International is held by insiders.

Percentage Held by Institutions

98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/17/2026
• Investor Day 2026: 9/24/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:CRL
• CIK: 1100682
• Web: www.criver.com
• Phone: (781) 222-6000
• Fax: 978-988-5665
• Employees: 19,700
• Year Founded: 1947

Price Target and Rating

• Average Price Target for Charles River Laboratories International: $273.81
• High Price Target: $330.00
• Low Price Target: $175.00
• Potential Upside/Downside: -2.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 24.86
• P/E Growth: 2.68
• Net Income: -$144.34 million
• Net Margins: -5.96%
• Pretax Margin: -4.59%
• Return on Equity: 15.75%
• Return on Assets: 6.51%

Debt

• Debt-to-Equity Ratio: 0.92
• Current Ratio: 1.35
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: $4.02 billion
• Price / Sales: 3.35
• Cash Flow: $22.60 per share
• Price / Cash Flow: 12.46
• Book Value: $64.39 per share
• Price / Book: 4.37

Miscellaneous

• Outstanding Shares: 47,740,000
• Free Float: 47,118,000
• Market Cap: $13.44 billion
• Optionable: Optionable
• Beta: 1.40